Trubion gains $52M in lackluster IPO

Trubion Pharmaceuticals went public on Tuesday, raising about $52 million as it sold shares at the bottom of its price range. Trubion had outlined plans to raise up to $86 million. Still, just completing the IPO was a success for the biotech. Light Sciences Oncology delayed its IPO plans, citing a weak market. Trubion, which was a 2006 Fierce 15 Winner, attracted considerable attention earlier this year when it signed a development deal with Wyeth worth up to $800 million.

- here's the Seattle Post-Intelligencer report on the IPO

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.